









Markets
/
Stocks
/
nasdaq-atra
/

Atara Biotherapeutics Inc

ATRA

4.610USD

-0.100-2.12%

Market hours （ET）Quotes delayed by 15 min

3.58MMarket Cap

1.77P/E TTM



Atara Biotherapeutics Inc

4.610

-0.100-2.12%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Atara Biotherapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Atara Biotherapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 160 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 9.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Atara Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

160 / 391

Overall Ranking

289 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Atara Biotherapeutics Inc Highlights

StrengthsRisks

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1308.75% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 1.76, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.30M shares, increasing 0.09% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 30.04K shares of this stock.

Analyst Rating

Based on 4 analysts

Hold

Current Rating

9.333

Target Price

+98.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Atara Biotherapeutics Inc is 7.13, ranking 129 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.59M, representing a year-over-year decrease of 95.13%, while its net profit experienced a year-over-year decrease of 73.17%.

Score

Industry at a Glance

Previous score

7.13

Change



Financials

4.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.06

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.82

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Atara Biotherapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Atara Biotherapeutics Inc is 7.36, ranking 127 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 1.76, which is 1121.15% below the recent high of 21.51 and 3561.97% above the recent low of -60.98.

Score

Industry at a Glance

Previous score

7.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 160/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Atara Biotherapeutics Inc is 6.40, ranking 336 out of 391 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 18.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

6.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Hold

Current Rating

9.333

Target Price

+98.16%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Atara Biotherapeutics Inc

ATRA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Atara Biotherapeutics Inc is 4.41, ranking 343 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.40 and the support level at 3.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.36

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.128

Sell

RSI(14)

39.662

Neutral

STOCH(KDJ)(9,3,3)

3.012

Oversold

ATR(14)

0.604

Low Volatility

CCI(14)

-80.101

Neutral

Williams %R

99.799

Oversold

TRIX(12,20)

-0.175

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.819

Sell

MA10

5.023

Sell

MA20

5.436

Sell

MA50

5.064

Sell

MA100

9.755

Sell

MA200

10.807

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Atara Biotherapeutics Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 60.83%, representing a quarter-over-quarter decrease of 22.00%. The largest institutional shareholder is The Vanguard, holding a total of 225.94K shares, representing 2.76% of shares outstanding, with 15.15% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture

1.41M

+5.59%

Adiumentum Capital Fund I LP

1.28M

+13.33%

EcoR1 Capital, LLC

573.18K

Redmile Group, LLC

441.70K

The Vanguard Group, Inc.

Star Investors

203.44K

+6.65%

Marshall Wace LLP

115.80K

+173.39%

BlackRock Institutional Trust Company, N.A.

64.42K

-1.23%

Geode Capital Management, L.L.C.

60.53K

+0.65%

Mackenzie Financial Corporation

63.82K

+183.45%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Atara Biotherapeutics Inc is 2.51, ranking 220 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.